not tagged
bms
dr discusses the golden age of immunotherapy with the challenging need to overcome intrinsic immune deficiencies with limited duration of therapy and higher cure rate. #ims2022 
Patient & CEO at @IMFMYELOMA  https://t.co/uQjumfRX1I | 26  year #myeloma patient https://t.co/Fj5nMt9Zmq | Personal views